<DOC>
	<DOCNO>NCT00896779</DOCNO>
	<brief_summary>Patients low vision ( visual acuity 20/400 worse ) exclude large Phase III ranibizumab clinical trial . It known treatment ranibizumab result improve visual function patients.Since ranibizumab show effective therapy exudative macular degeneration propose treat patient study monthly ranibizumab intravitreal injection . Patients assign one two group flip coin . Group # 1 `` head '' Group # 2 `` tail '' . Group # 1 patient treat 3 monthly injection 0.5 mg ranibizumab need therapy . Group # 2 treat 6 monthly injection 0.5 mg ranibizumab need therapy .</brief_summary>
	<brief_title>Lucentis Advanced Macular Degeneration</brief_title>
	<detailed_description>The duration study 13 month . This include 30 day test perform treatment . Only one eye chosen study . Patients receive 12 injection ranibizumab study ( first dose [ ] , plus additional dos [ treatment often every 22 day ] doctor determine additional dos require ) . In addition study drug injection . Several eye examination procedure perform evaluate response treatment . These include : visual acuity testing ( eye chart ) , contrast sensitivity testing , read speed testing , measurement time complete typical daily activity , measurement thickness central retina , measurement central visual field . On screen visit two time study fluorescein angiography perform . The screening test include follow : - A review medical history - A review medication take - Eye examination , include visual acuity testing ( read letter eye chart ) - Blood pressure measurement Woman childbearing potential must also take urine pregnancy test screening period rule pregnancy . Upon completion study Month 12 occur ; early termination visit , follow procedure perform : vision exam , OCT , microperimetry , FA/Photos , VFQ , read performance , contrast sensitivity TIADL .</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Subjects eligible follow criterion meet : Ability provide write informed consent comply study assessment full duration study . Age &gt; 50 year . Low vision AMD patient VA 20/400 worse . Evidence active exudation manifest subretinal intraretinal fluid OCT fresh appear subretinal hemorrhage fundus examination . Subjects meet follow criterion exclude study : Pregnancy ( positive pregnancy test ) lactation . Premenopausal woman use adequate contraception . The following consider effective mean contraception : surgical sterilization use oral contraceptive , barrier contraception either condom diaphragm conjunction spermicidal gel , IUD , contraceptive hormone implant patch . Any condition investigator believe would pose significant hazard subject investigational therapy initiate . Participation another simultaneous medical investigation trial . Concurrent eye disease study eye could compromise visual acuity ( e.g. , diabetic retinopathy , advanced glaucoma ) .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>